ReviewInternational journal of hematology2018
Chinese guidelines for treatment of adult primary immune thrombocytopenia.
Review in International journal of hematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04913597 (A Prospective Observational Study of Switching Avatrombopag and Rh-TPO in Chinese Adult Patients With Primary Immune Thrombocytopenia), which is not on this map. Cited by 39 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective Observational Study of Switching Avatrombopag and Rh-TPO in Chinese Adult Patients With Primary Immune Thrombocytopenia
Who cites it
39 citing papers in PubMed, 4 syntheses or guidelines pooled it, 76 citations in OpenAlex.
- [Chinese guideline on the diagnosis and treatment of adult primary immune thrombocytopenia (2025)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Guideline
- Comparative efficacy and safety of rhTPO, romiplostim, and eltrombopag in the treatment of pediatric primary immune thrombocytopenia: a systematic review and network meta-analysis.Frontiers in immunology · 2025Pooled it
- [Chinese guideline on the diagnosis and management of adult primary immune thrombocytopenia (version 2020)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2020Guideline
- Safety and efficacy of eltrombopag in the treatment of children with immune thrombocytopenia: a Meta analysis.Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatricsPooled it
- A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.Journal of hematology & oncology · 2021Trial
- Effect of postdose fasting duration on hetrombopag olamine pharmacokinetics and pharmacodynamics in healthy volunteers.British journal of clinical pharmacology · 2020Trial
- Artificial intelligence prediction of therapy response in newly diagnosed adult severe primary immune thrombocytopenia.Research and practice in thrombosis and haemostasis · 2026Article
- [Bleeding characteristics in pregnant patients with immune thrombocytopenia and severe thrombocytopenia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- Recombinant human thrombopoietin for chronic liver disease-associated thrombocytopenia with or without concomitant infections: a real-world retrospective study.Frontiers in pharmacology · 2026Article
- Real-world experience of hetrombopag in immune thrombocytopenia treatment: a retrospective cohort study.European journal of medical research · 2025Article
- Dynamic changes in platelet counts and psychological state in ITP patients after COVID-19 infection.Frontiers in medicine · 2025Article
- Decreased Expression of IL-35 and Its Receptor Contributes to Impaired Megakaryopoiesis in the Pathogenesis of Immune Thrombocytopenia.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Challenges in treating primary immune thrombocytopenia patients undergoing COVID-19 vaccination: A retrospective study.Open medicine (Warsaw, Poland) · 2024Article
- Therapeutic Outcomes of High Dose-Dexamethasone versus Prednisolone + Azathioprine, Rituximab, Eltrombopag, and Romiplostim Strategies in Persistent, Chronic, Refractory, and Relapsed Immune Thrombocytopenia Patients.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Combination of two target agonists of the thrombopoietin and thrombopoietin receptor in the treatment of elderly patients with refractory immune thrombocytopenia.Cancer pathogenesis and therapy · 2023Article
- How we treat primary immune thrombocytopenia in adults.Journal of hematology & oncology · 2023Review
- The association between platelet glycoprotein-specific antibodies and response to short-term high-dose dexamethasone with prednisone maintenance treatment in adult patients with primary immune thrombocytopenia.Annals of medicine · 2022Article
- Clinical characteristics in immune thrombocytopenia patients after COVID-19 vaccination.Human vaccines & immunotherapeutics · 2022Article
- Recombinant Thrombopoietin Effectively Shortens the Time to Response and Increases Platelet Counts in Elderly Patients with Severe Immune Thrombocytopenia.Journal of clinical medicine · 2022Article
- Impaired mitochondria of Tregs decreases OXPHOS-derived ATP in primary immune thrombocytopenia with positive plasma pathogens detected by metagenomic sequencing.Experimental hematology & oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
42 authors at 20 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary immune thrombocytopenia (ITP) is a bleeding disorder commonly encountered in clinical practice. The International Working Group (IWG) on ITP has published several landmark papers on terminology, definitions, outcome criteria, bleeding assessment, diagnosis, and management of ITP. The Chinese consensus reports for diagnosis and management of adult ITP have been updated to the 4th edition. Based on current consensus positions and new emerging clinical evidence, the thrombosis and hemostasis group of the Chinese Society of Hematology issued Chinese guidelines for management of adult ITP, which aim to provide evidence-based recommendations for clinical decision making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.